ARWR vs LLY

Arrowhead Pharmaceuticals retains its strong 10x growth potential within the next 3-5 years. The Q1 2026 financials (fiscal quarter ended Dec 31, 2025) showcased a significant revenue beat of $264.0M and a positive net margin of 18.54%, driven by the successful commercial launch of Redemplo. Critically, the strong two-year efficacy data for plozasiran (83% triglyceride reduction) and anticipated s...

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...